Asia PR News

BILLERICA, Mass. and CARLSBAD, Calif., July 31 /PRNewswire-AsiaNet/ –

Bruker Daltonics, a subsidiary of Bruker BioSciences (Nasdaq: BRKR), and
Isis Pharmaceuticals (Nasdaq: ISIS) announce today a strategic alliance for
manufacturing and distribution of Isis’ Ibis T5000(TM) biosensor system. The
Ibis T5000, developed by Isis’ Ibis Biosciences(TM) division, is a universal
biosensor system that can simultaneously identify thousands of types of
infectious organisms in a sample, without needing to know beforehand what
might be present in the sample.

(Photo: http://www.newscom.com/cgi-bin/prnh/20060731/NYM038 )
In this strategic alliance, Bruker Daltonics will be the exclusive
worldwide manufacturer of the Ibis T5000 biosensor system, which incorporates
Bruker Daltonics’ micrOTOF(TM) ESI-TOF mass spectrometer. Bruker Daltonics
will also be responsible for order processing, system installations and
service in North America, Europe and the Middle East. In Europe and the
Middle East, Bruker Daltonics will have exclusive rights to sell Ibis T5000
systems and Ibis infectious organism identification kits for various
government applications, and non-exclusive rights to sell to all other
customers, including clinical, pharmaceutical and academic researchers for all
other applications except diagnostics. Outside of Bruker Daltonics’ exclusive
market, Isis may sell Ibis T5000s and its infectious organism identification
kits.

The Ibis T5000 utilizes the Triangulation Identification for the Genetic
Evaluation of Risks (T.I.G.E.R.) methodology, which is a combination of
genomics, mathematical modeling, mass spectrometry and molecular
amplification, to generate a "fingerprint" of each bacterium or virus,
allowing it to identify virtually any bacteria or virus present in a sample.
In addition, the Ibis T5000 biosensor system can rapidly identify or classify
organisms that are newly-emerging, genetically altered or unculturable. The
Ibis T5000 biosensor works with many different types of infectious samples
from human samples, such as throat swabs or sputum, to environmental samples,
such as soil or air. The Ibis T5000 is currently designated for Research Use
Only (RUO) and has not been approved for any regulated uses, including in
vitro diagnostics.

"Utilizing our mass spectrometry instrumentation, the Ibis division at
Isis Pharmaceuticals has pioneered a universal biosensor system that with the
appropriate reagents and databases has the potential to meet unmet infectious
disease identification needs both in the government and in important clinical
and pharmaceutical research markets," said Frank Laukien, President of Bruker
Daltonics. "The Ibis T5000 system can identify or classify and quantify a
broad range of pathogens, and also can yield details on strain type and drug
resistance. In the future, this additional information can potentially
support rapid, informed responses, for instance, in monitoring infectious
disease outbreaks or in identifying the sources of hospital-acquired
infections. Our strategic alliance will allow Ibis to take advantage of our
instrument manufacturing capabilities, global distribution channels and
service network, while we benefit from Ibis’ technology expertise and the
outstanding capabilities of the Ibis T5000 biosensor system."

"This alliance is a major milestone in commercializing our Ibis T5000
biosensor system. We have been working with Bruker Daltonics for over nine
years and as the relationship has evolved, Bruker was an obvious partner for
the manufacturing, distribution and service of the Ibis T5000 biosensor
system," said Michael Treble, President of the Ibis Biosciences division and
Vice President of Isis Pharmaceuticals. "Combining Bruker Daltonics’
worldwide presence and instrument manufacturing expertise with our proprietary
infectious disease identification technology is a key component of our
commercialization strategy for the Ibis T5000 system. We anticipate that this
relationship will immediately help us with this year’s planned
commercialization to our early-access customers, and overall we expect that
working with Bruker Daltonics will expand the reach of the Ibis T5000
biosensor system within the U.S. and overseas markets for various government
and medical research applications."

ABOUT THE IBIS T5000 BIOSENSOR SYSTEM AND IBIS BIOSCIENCES DIVISION
Isis’ Ibis Biosciences division has developed the Ibis T5000 biosensor
system, which uses the Triangulation Identification for the Genetic Evaluation
of Risks (T.I.G.E.R.) methodology to identify infectious organisms. Ibis
plans to commercialize the Ibis T5000 biosensor system and associated reagents
to government customers for use in biowarfare defense, epidemiological
surveillance and forensics; and to non-government customers for use in
pharmaceutical process control, hospital-associated infection control and
infectious disease diagnostics. Additional information about Isis’ Ibis
division can be found by selecting the Ibis Biosciences link from Isis’
homepage at http://www.isispharm.com.

The Ibis Biosciences division has been funded by U.S. government agencies
including the Defense Advanced Research Projects Agency (DARPA), the National
Institute of Allergy and Infectious Diseases (NIAID), part of the National
Institutes of Health (NIH), the Centers for Disease Control and Prevention
(CDC), the Federal Bureau of Investigation (FBI), the Department of Homeland
Security (DHS), and others.

ABOUT BRUKER BIOSCIENCES
Bruker BioSciences Corporation in Billerica, Massachusetts is the parent
company of Bruker AXS Inc., Bruker Daltonics Inc. and Bruker Optics, Inc.
Bruker AXS is a leading developer and provider of life science, materials
research and industrial X-ray analysis tools. Bruker Daltonics is a leading
developer and provider of innovative life science tools based on mass
spectrometry, and also offers a broad line of nuclear, biological and chemical
(NBC) detection products for homeland security. Bruker Optics is a leading
developer, manufacturer and provider of research, analytical and process
analysis instruments and solutions based on infrared and Raman molecular
spectroscopy technology. For more information, please visit
http://www.bruker-biosciences.com.

ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its expertise in RNA to discover and develop novel
drugs for its product pipeline and for its partners. The Company has
successfully commercialized the world’s first antisense drug and has 15 drugs
in development. Isis’ drug development programs are aimed at treating
cardiovascular, metabolic and inflammatory diseases. Isis’ partners are
focused in disease areas such as inflammatory, ocular, viral and
neurodegenerative diseases, and cancer. In its Ibis Biosciences division,
Isis is developing and commercializing the Ibis T5000 biosensor system, a
revolutionary system to identify infectious organisms. As an innovator in
RNA-based drug discovery and development, Isis is the owner or exclusive
licensee of approximately 1,500 issued patents worldwide. Additional
information about Isis is available at http://www.isispharm.com.

CAUTIONARY STATEMENT OF ISIS AND BRUKER BIOSCIENCES
This press release includes forward-looking statements regarding Isis’
agreement with Bruker Daltonics and the development and commercialization of
the Ibis T5000 biosensor system and related products, as well as both
companies’ plans and goals for the alliance. Any statement describing Isis’
or Bruker’s goals, expectations, intentions or beliefs is a forward-looking
statement and should be considered an at-risk statement. Such statements are
subject to certain risks and uncertainties, particularly those inherent in
developing and commercializing systems to identify infectious organisms that
are effective and commercially attractive, and in the endeavor of building a
business around such products. Isis’ and Bruker’s forward-looking statements
also involve assumptions that, if they never materialize or prove correct,
could cause its results to differ materially from those expressed or implied
by such forward-looking statements. Although Isis’ and Bruker’s forward-
looking statements reflect the good faith judgment of its management, these
statements are based only on facts and factors currently known by Isis and
Bruker. As a result, you are cautioned not to rely on these forward-looking
statements. These and other risks are described in additional detail in Isis’
and Bruker’s respective annual reports on Form 10-K for the year ended
December 31, 2005, and their respective quarterly reports on Form 10-Q for the
quarter ended March 31, 2006, which are on file with the SEC. Copies of these
and other documents are available from the companies.

Ibis Biosciences(TM) is a trademark of Isis Pharmaceuticals, Inc.
Ibis T5000(TM) is a trademark of Isis Pharmaceuticals, Inc.

SOURCE: Bruker Daltonics

CONTACT: Michael Willett, Investor and Public Relations Officer of
Bruker Daltonics, +1-978-663-3660, ext. 1411, ir@bruker-
biosciences.com; or Kate Corcoran, Ph.D., Vice President
of Corporate Development of Isis Pharmaceuticals, +1-760-603-2331/

/Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20060731/NYM038
AP Archive: http://photoarchive.ap.org
AP PhotoExpress Network: PRN1
PRN Photo Desk, photodesk@prnewswire.com/

Web site: http://www.bruker-biosciences.com
http://www.isispharm.com /
(BRKR ISIS)